Grifols has announced it has acquired 60 percent of Spanish biotechnology firm Progenika Biopharma.
Grifols, headquartered in Barcelona, Spain, is one of the world’s largest producers of plasma medicines.
Progenika, headquartered in Vizcaya, Spain, designs, produces and commercializes in vitro diagnostics tests.
Grifols acquired the majority stake in Progenika for 37 million Euros (~$48 million).